MX2017015011A - Ensayo a base de celulas para detectar homodimeros anti-cd3. - Google Patents
Ensayo a base de celulas para detectar homodimeros anti-cd3.Info
- Publication number
- MX2017015011A MX2017015011A MX2017015011A MX2017015011A MX2017015011A MX 2017015011 A MX2017015011 A MX 2017015011A MX 2017015011 A MX2017015011 A MX 2017015011A MX 2017015011 A MX2017015011 A MX 2017015011A MX 2017015011 A MX2017015011 A MX 2017015011A
- Authority
- MX
- Mexico
- Prior art keywords
- cell
- homodimers
- based assay
- detecting anti
- tdb
- Prior art date
Links
- 238000000423 cell based assay Methods 0.000 title abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 230000006044 T cell activation Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
Abstract
La presente invención proporciona un ensayo a base de células para identificar y/o cuantificar homodímeros anti-CD3 en una composición que comprende un anticuerpo biespecífic dependiente de linfocitos T (TDB). En algunos aspectos, los linfocitos T de la invención que comprenden un indicador que responde a la activación de linfocitos T están en contacto con el TDB para detectar la presencia de homodímeros anti- CD3. También se contemplan las composiciones de linfocitos T indicadores y kits.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562167761P | 2015-05-28 | 2015-05-28 | |
PCT/US2016/034868 WO2016191750A1 (en) | 2015-05-28 | 2016-05-27 | Cell-based assay for detecting anti-cd3 homodimers |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017015011A true MX2017015011A (es) | 2018-03-23 |
Family
ID=56236065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017015011A MX2017015011A (es) | 2015-05-28 | 2016-05-27 | Ensayo a base de celulas para detectar homodimeros anti-cd3. |
Country Status (16)
Country | Link |
---|---|
US (2) | US10690678B2 (es) |
EP (2) | EP3795679A1 (es) |
JP (1) | JP6810058B2 (es) |
KR (1) | KR102583058B1 (es) |
CN (1) | CN107646038B (es) |
AU (1) | AU2016267691B2 (es) |
BR (1) | BR112017025051A2 (es) |
CA (1) | CA2987403A1 (es) |
ES (1) | ES2823033T3 (es) |
HK (1) | HK1250045A1 (es) |
HR (1) | HRP20201779T1 (es) |
IL (1) | IL255696B (es) |
MX (1) | MX2017015011A (es) |
SG (1) | SG10201911335TA (es) |
SI (1) | SI3303400T1 (es) |
WO (1) | WO2016191750A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20210107A1 (es) | 2013-12-17 | 2021-01-19 | Genentech Inc | Anticuerpos anti-cd3 y metodos de uso |
AU2015314744A1 (en) | 2014-09-12 | 2017-03-02 | Genentech, Inc. | Anti-CLL-1 antibodies and immunoconjugates |
CN107847568B (zh) | 2015-06-16 | 2022-12-20 | 豪夫迈·罗氏有限公司 | 抗cll-1抗体和使用方法 |
PE20180330A1 (es) | 2015-06-16 | 2018-02-13 | Genentech Inc | Anticuerpos madurados por afinidad y humanizados para fcrh5 y metodos para su uso |
US11513127B2 (en) | 2016-01-25 | 2022-11-29 | Genentech, Inc. | Methods for assaying T-cell dependent bispecific antibodies |
CA3042435A1 (en) | 2016-11-15 | 2018-05-24 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
CN110114674B (zh) * | 2016-12-13 | 2023-05-09 | 豪夫迈·罗氏有限公司 | 确定肿瘤样品中存在靶抗原的方法 |
MA51793A (fr) | 2018-02-08 | 2020-12-16 | Hoffmann La Roche | Molécules bispécifiques de liaison à l'antigène et procédés d'utilisation |
CN108918892B (zh) * | 2018-08-01 | 2021-04-27 | 百奥泰生物制药股份有限公司 | 一种测定抗vegf抗体活性的方法及其应用 |
TW202028244A (zh) * | 2018-10-09 | 2020-08-01 | 美商建南德克公司 | 用於確定突觸形成之方法及系統 |
AU2020403145A1 (en) | 2019-12-13 | 2022-07-07 | Genentech, Inc. | Anti-Ly6G6D antibodies and methods of use |
CN111077311B (zh) * | 2019-12-30 | 2023-05-09 | 北京立康生命科技有限公司 | 一种酶联免疫斑点检测试剂盒及其检测方法 |
CN112433055A (zh) * | 2020-11-04 | 2021-03-02 | 上海药明生物技术有限公司 | 一种基于报告基因方法检测pvrig抗体的生物学活性的方法 |
CN112458149B (zh) * | 2020-12-03 | 2021-10-08 | 北京东方百泰生物科技股份有限公司 | 一种以cd3为靶点的抗体药物对t细胞激活程度的检测方法 |
CN112921004B (zh) * | 2021-02-05 | 2023-08-08 | 上海精翰生物科技有限公司 | 用于cd3受体激动剂检测的细胞株及其构建方法及cd3受体激动剂检测方法 |
CN114395047B (zh) * | 2021-12-07 | 2023-11-07 | 合肥天港免疫药物有限公司 | 双特异性抗体及其应用 |
WO2023250485A1 (en) | 2022-06-23 | 2023-12-28 | LAVA Therapeutics N.V. | Assay for t cell dependent multispecific compounds |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0308936B1 (en) | 1987-09-23 | 1994-07-06 | Bristol-Myers Squibb Company | Antibody heteroconjugates for the killing of HIV-infected cells |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
EP0479909B1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
CA2086417C (en) | 1990-06-29 | 1999-07-06 | Biosource Technologies, Inc. | Melanin production by transformed organisms |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
ES2241710T3 (es) | 1991-11-25 | 2005-11-01 | Enzon, Inc. | Procedimiento para producir proteinas multivalentes de union a antigeno. |
DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
DE69333082T2 (de) | 1992-02-11 | 2004-05-06 | Cell Genesys, Inc., Foster City | Erzielen von homozygotem durch zielgerichtete genetische ereignisse |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
WO1994011026A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
WO2002051870A2 (en) | 2000-12-22 | 2002-07-04 | GRAD, Carole Legal Representative of KAPLAN, Howard | Phage display libraries of human vh fragments |
JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
EP2221317A3 (en) | 2003-06-30 | 2011-07-27 | Domantis Limited | PEGylated single domain antibodies (dAb) |
AU2005285347A1 (en) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
NZ580115A (en) | 2004-09-23 | 2010-10-29 | Genentech Inc | Cysteine engineered antibody light chains and conjugates |
ES2774337T3 (es) | 2008-01-07 | 2020-07-20 | Amgen Inc | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
CA2999385A1 (en) | 2015-09-23 | 2017-03-30 | Regeneron Pharmaceuticals, Inc. | Optimized anti-cd3 bispecific antibodies and uses thereof |
-
2016
- 2016-05-27 ES ES16732377T patent/ES2823033T3/es active Active
- 2016-05-27 SG SG10201911335TA patent/SG10201911335TA/en unknown
- 2016-05-27 MX MX2017015011A patent/MX2017015011A/es unknown
- 2016-05-27 JP JP2017561777A patent/JP6810058B2/ja active Active
- 2016-05-27 EP EP20190490.1A patent/EP3795679A1/en not_active Withdrawn
- 2016-05-27 CN CN201680030308.8A patent/CN107646038B/zh active Active
- 2016-05-27 AU AU2016267691A patent/AU2016267691B2/en active Active
- 2016-05-27 WO PCT/US2016/034868 patent/WO2016191750A1/en active Application Filing
- 2016-05-27 KR KR1020177036974A patent/KR102583058B1/ko active IP Right Grant
- 2016-05-27 BR BR112017025051-9A patent/BR112017025051A2/pt active Search and Examination
- 2016-05-27 CA CA2987403A patent/CA2987403A1/en active Pending
- 2016-05-27 EP EP16732377.3A patent/EP3303400B1/en active Active
- 2016-05-27 SI SI201631004T patent/SI3303400T1/sl unknown
-
2017
- 2017-11-15 IL IL255696A patent/IL255696B/en unknown
- 2017-11-28 US US15/824,992 patent/US10690678B2/en active Active
-
2018
- 2018-07-23 HK HK18109493.3A patent/HK1250045A1/zh unknown
-
2020
- 2020-05-14 US US16/874,550 patent/US20200378987A1/en active Pending
- 2020-11-04 HR HRP20201779TT patent/HRP20201779T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
AU2016267691B2 (en) | 2022-06-16 |
JP2018521635A (ja) | 2018-08-09 |
WO2016191750A1 (en) | 2016-12-01 |
JP6810058B2 (ja) | 2021-01-06 |
AU2016267691A1 (en) | 2017-12-21 |
CN107646038A (zh) | 2018-01-30 |
IL255696B (en) | 2022-04-01 |
ES2823033T3 (es) | 2021-05-05 |
EP3303400B1 (en) | 2020-09-09 |
BR112017025051A2 (pt) | 2018-08-07 |
US20200378987A1 (en) | 2020-12-03 |
EP3795679A1 (en) | 2021-03-24 |
CA2987403A1 (en) | 2016-12-01 |
EP3303400A1 (en) | 2018-04-11 |
US20180267055A1 (en) | 2018-09-20 |
SG10201911335TA (en) | 2020-01-30 |
HK1250045A1 (zh) | 2018-11-23 |
HRP20201779T1 (hr) | 2021-01-22 |
IL255696A (en) | 2018-01-31 |
SI3303400T1 (sl) | 2021-01-29 |
US10690678B2 (en) | 2020-06-23 |
CN107646038B (zh) | 2021-08-20 |
KR20180013986A (ko) | 2018-02-07 |
KR102583058B1 (ko) | 2023-09-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017015011A (es) | Ensayo a base de celulas para detectar homodimeros anti-cd3. | |
MX2020014089A (es) | Metodos, kits y aparato para expandir una poblacion de celulas. | |
WO2018136562A3 (en) | Compositions and methods for immune repertoire sequencing | |
WO2014153651A8 (en) | Microfluidic devices and methods for use thereof in multicellular assays of secretion | |
WO2014186761A3 (en) | Methods for determining responsiveness to an anti-cd47 agent | |
EA201600085A1 (ru) | Набор для обнаружения соевого события syht0h2 | |
BR112014025384A8 (pt) | método e sistema para executar ensaio automatizado e métodos para executar teste reflexivo em vários exemplares | |
MX2016013255A (es) | Metodos y composiciones para detectar proteinas mal plegadas. | |
BR112016004437A2 (pt) | métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit | |
MX347964B (es) | Metodos y kits para la deteccion de células tumorales circulantes en pacientes pancreáticos por medio del uso de captura poliespecífica y reactivos de detección de cocteles. | |
NZ629703A (en) | Methods and compositions for detecting multiple analytes with a single signal | |
MY192493A (en) | Urinalysis device and dry reagent for quantitative urinalysis | |
MX2017005750A (es) | Ensayos para detectar subgrupos inmunes de células t y sus métodos de uso. | |
AR105618A1 (es) | Metilación del promotor del ligando al receptor de muerte programada (pd-l1) en cáncer | |
MX2019002578A (es) | Métodos de detección de la expresión del ligando 1 de muerte programada por célula y usos de los mismos. | |
MX2017000083A (es) | Compuestos de platino, composiciones y usos de estos. | |
EA201390638A8 (ru) | Обогащение и идентификация фетальных клеток в материнской крови и лиганды для такого применения | |
MX2018013621A (es) | Metodo, matriz y uso de estos. | |
WO2015189591A3 (en) | Method and arrays for use in diagnosing early breast cancer | |
MX2017007232A (es) | Ensayos de desplazamiento por movilidad homogeneos indirectos para la deteccion de productos biologicos en muestras de pacientes. | |
GB2542576A (en) | Method and kit of detecting the absence of micro-oranisms | |
MX2016001719A (es) | Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular. | |
WO2014151290A3 (en) | Assay for predictive biomarkers | |
MX2015013993A (es) | Procedimientos y series para su uso en los mismos. | |
MX2020002787A (es) | Metodo para el analisis de metilacion. |